

SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 07/17/18

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	Reduce the risk of major adverse cardiac events (MACE) in patients with Chronic Heart Failure and significant Coronary Artery Disease (2) Prevention of Symptomatic VTE and VTE-related death in high-risk, medically ill pts (2) Reduce the risk of MACE in patients with coronary or Peripheral Artery Disease (2) VTE prophylaxis in ambulatory cancer patients receiving chemo at high-risk for VTE (2) Infrainguinal revascular (2) Pediatric VTE (2)	Phase III Phase III Filed 12/17 Phase III Phase III Phase III	
	INVOKANA® (canagliflozin)	Diabetic Nephropathy (2) Reduce the composite risk of CV death, MI or stroke in type 2 diabetes with established, or risk for, cardiovascular disease. (CANVAS /CANVAS-R) (2)	Phase III Filed 9/17	Phase III Filed 10/17
Immunology	TREMFYA® (guselkumab)	Psoriatic arthritis Psoriasis Patient-Controlled Injector Crohn's Disease	Phase III Filed 3/18 Phase III	Phase III Filed 4/18 Phase III
	SIMPONI ARIA® (golimumab) STELARA® (ustekinumab)	Juvenile Idiopathic Arthritis (JIA) Pediatric Psoriasis (6-12 year olds) Ulcerative Colitis Lupus	Phase III Phase III Phase III Phase III	Phase III Phase III Phase III Phase III
Infectious Diseases and Vaccines	SYMTUZA™ (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)	Single tablet regimen for HIV in treatment naïve patients and treatment experienced patients (2)	Filed 9/17	Approved 9/17
	JULUCA® (rilpivirine and dolutegravir)	Single tablet regimen for HIV in treatment experienced patients (2)	Approved 11/17	Approved 5/18
	Rilpivirine Long Acting nanosuspension for injection pimodivir (JNJ-3872)	HIV Infection Influenza A (2)	Phase III Phase III	Phase III Phase III
Neuroscience	esketamine	Treatment-resistant depression Major depressive disorder with imminent risk for suicide	Phase III Phase III	Phase III Phase III
	ponesimod	Relapsing multiple sclerosis	Phase III	Phase III
	paliperidone palmitate 6 month long-acting injectable	Maintenance treatment of schizophrenia	Phase III	Phase III
Oncology	DARZALEX®	Frontline multiple myeloma transplant eligible in combination with bortezomib, thalidomide and dexamethasone (MMY 3006) (2)	Phase III	Phase III
		Frontline multiple myeloma transplant ineligible patients in combination with bortezomib, melphalan, and prednisone (MMY 3007) (2)	Approved 5/18	Filed 11/17
		Frontline multiple myeloma transplant ineligible patients in combination with lenalidomide and low dose dexamethasone (MMY 3008) (2)	Phase III	Phase III
		Relapsed Refractory MM 1+ prior lines w/PomDex (2)	Phase III	Phase III
		Relapsed Refractory multiple myeloma w/carfilzomib/dex (Amgen sponsored) (2)	Phase III	Phase III
		Amyloidosis (AMY 3001) (2)	Phase III	Phase III
		Subcutaneous (SC) formulation (MMY3012) (2)	Phase III	Phase III
	IMBRUVICA® (ibrutinib)	Smoldering multiple myeloma (SMM3001) (2)	Phase III	Phase III
		Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-3002) (2)	Phase III	Phase III
		Relapsed/refractory patients with Indolent Non-Hodgkins Lymphoma in combination with Bendamustine and Rituximab or R-CHOP; (randomized study FLR-3001) (2)	Phase III	Phase III
		Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma in combination with R-CHOP (randomized study DBL3001) (2)	Phase III	Phase III
		Previously Treated Adults with Waldenström's Macroglobulinemia with Rituximab (PCYC-1127) (2)	Filed 04/18	Phase III
	ERLEADA™ (apalutamide)	Frontline Chronic Lymphocytic Leukemia (Young and Fit) (in combination with Rituximab) (ECOG 1912) (2)	Phase III	Phase III
Frontline Chronic Lymphocytic Leukemia in combination with obinutuzumab (PCYC-1130) (2)		Phase III	Phase III	
Frontline Chronic Lymphocytic Leukemia IV fixed duration (CLL-3011) (2)		Phase III	Phase III	
Frontline Chronic graft-versus-host-disease (cGVHD) (2)		Phase III	Phase III	
Prostate cancer non-metastatic castration-resistant Metastatic hormone sensitive prostate cancer Localized prostate cancer		Approved 02/18 Phase III Phase III	Filed 02/18 Phase III Phase III	
apalutamide/ abiraterone acetate	Prostate Cancer metastatic castration resistant chemotherapy naïve	Phase III	Phase III	
Pulmonary Hypertension	OPSUMIT®	Fontan-palliated in adolescent (>12 years old) and adult patients Pediatric pulmonary arterial hypertension Chronic thromboembolic pulmonary hypertension	Phase III Phase III Filed 4/18	Phase III Phase III Phase II
	UPTRAVI® IV	Pulmonary arterial hypertension	Phase III	Phase III

* This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

(2) INVOKANA licensed from Mitsubishi Tanabe Pharma Corporation; SYMTUZA developed in collaboration with Gilead Sciences; EDURANT STR developed in collaboration with Viiv Healthcare; XARELTO co-developed with Bayer HealthCare; paliperidone palmitate includes technology licensed from Alkermes, Inc.; DARZALEX licensed from Genmab A/S; IMBRUVICA developed in collaboration with Pharmacyclics, LLC, an AbbVie company
Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.;

Janssen Pharmaceutical Companies of Johnson & Johnson
Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings*
 Selective Highlights as of July 17, 2018

NMEs APPROVED 2017/2018	NMEs IN REGISTRATION	NME PLANNED FILINGS 2018-2021*	
Immunology	Oncology	Oncology	Neuroscience
TREMFYA® (guselkumab) Psoriasis	ERLEADA™ (apalutamide) (EU) Non-metastatic prostate cancer	Imetelstat Myelofibrosis	Esketamine Treatment resistant depression
Oncology		Erdafitinib (FGFR1 kinase inhibitor) Urothelial cancer	Ponesimod Relapsing multiple sclerosis
ERLEADA™ (apalutamide) (US) Non-metastatic prostate cancer		Niraparib Metastatic castration-resistant prostate cancer (mCRPC)	Infectious Diseases & Vaccines
		CAR-T (JNJ-4528) Multiple Myeloma	Lumicitabine (JNJ-1575) RSV infection
			Pimodivir (JNJ-3872) Influenza A

*Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Imetelstat licensed from Geron; Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; Erdafitinib discovered in collaboration with Astex Pharmaceuticals, Inc.; CAR-T licensed from Legend Biotech.

